Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Rümke HC[au]:

[Hypersensitivity reactions and vaccines]. Geersing TH et al. Ned Tijdschr Geneeskd. (2017)

Elevated Immune Response Among Children 4 Years of Age With Pronounced Local Adverse Events After the Fifth Diphtheria, Tetanus, Acellular Pertussis Vaccination. van der Lee S et al. Pediatr Infect Dis J. (2017)

[Reported adverse events following influenza vaccination]. van Balveren-Slingerland L et al. Ned Tijdschr Geneeskd. (2014)

Search results

Items: 1 to 50 of 111

1.

[Hypersensitivity reactions and vaccines].

Geersing TH, Hilgersom WJA, Tempels-Pavlica Ž, Rümke HC, de Koning LCMJ, Borgsteede SD.

Ned Tijdschr Geneeskd. 2017;161:D1491. Review. Dutch.

PMID:
29219793
2.

Elevated Immune Response Among Children 4 Years of Age With Pronounced Local Adverse Events After the Fifth Diphtheria, Tetanus, Acellular Pertussis Vaccination.

van der Lee S, Kemmeren JM, de Rond LGH, Öztürk K, Westerhof A, de Melker HE, Sanders EAM, Berbers GAM, van der Maas NAT, Rümke HC, Buisman AM.

Pediatr Infect Dis J. 2017 Sep;36(9):e223-e229. doi: 10.1097/INF.0000000000001620.

PMID:
28430750
3.

Adverse events and association with age, sex and immunological parameters of Q fever vaccination in patients at risk for chronic Q fever in the Netherlands 2011.

Schoffelen T, Wong A, Rümke HC, Netea MG, Timen A, van Deuren M, Vermeer-de Bondt PE.

Vaccine. 2014 Nov 20;32(49):6622-30. doi: 10.1016/j.vaccine.2014.09.061.

PMID:
25446824
4.

Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.

Vaccine. 2015 Jan 1;33(1):174-81. doi: 10.1016/j.vaccine.2014.10.085. Epub 2014 Nov 11.

PMID:
25444803
5.

Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.

Pediatr Infect Dis J. 2014 Dec;33(12):e320-9. doi: 10.1097/INF.0000000000000462.

PMID:
24978857
6.

[Reported adverse events following influenza vaccination].

van Balveren-Slingerland L, Rümke HC, Kant AC.

Ned Tijdschr Geneeskd. 2014;158:A6841. Dutch.

PMID:
24518843
7.

Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.

Rümke HC, Richardus JH, Rombo L, Pauksens K, Plaßmann G, Durand C, Devaster JM, Dewé W, Oostvogels L.

BMC Infect Dis. 2013 Jul 26;13:348. doi: 10.1186/1471-2334-13-348.

8.

Implementation of a Q fever vaccination program for high-risk patients in the Netherlands.

Isken LD, Kraaij-Dirkzwager M, Vermeer-de Bondt PE, Rümke HC, Wijkmans C, Opstelten W, Timen A.

Vaccine. 2013 May 28;31(23):2617-22. doi: 10.1016/j.vaccine.2013.03.062. Epub 2013 Apr 11.

PMID:
23583810
9.

Specific interferon γ detection for the diagnosis of previous Q fever.

Schoffelen T, Joosten LA, Herremans T, de Haan AF, Ammerdorffer A, Rümke HC, Wijkmans CJ, Roest HI, Netea MG, van der Meer JW, Sprong T, van Deuren M.

Clin Infect Dis. 2013 Jun;56(12):1742-51. doi: 10.1093/cid/cit129. Epub 2013 Mar 5.

PMID:
23463641
10.

Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.

Vesikari T, Hardt R, Rümke HC, Icardi G, Montero J, Thomas S, Sadorge C, Fiquet A.

Hum Vaccin Immunother. 2013 Apr;9(4):858-64. doi: 10.4161/hv.23412. Epub 2013 Jan 14.

11.

The burden of varicella from a parent's perspective and its societal impact in The Netherlands: an Internet survey.

Wolleswinkel-van den Bosch JH, Speets AM, Rümke HC, Gumbs PD, Fortanier SC.

BMC Infect Dis. 2011 Nov 17;11:320. doi: 10.1186/1471-2334-11-320.

12.

A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years.

Schwarz TF, Flamaing J, Rümke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2011 Jul 18;29(32):5195-202. doi: 10.1016/j.vaccine.2011.05.031. Epub 2011 May 25.

13.

Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses.

Rümke HC, Loch HP, Hoppenbrouwers K, Vandermeulen C, Malfroot A, Helm K, Douha M, Willems P.

Vaccine. 2011 May 17;29(22):3842-9. doi: 10.1016/j.vaccine.2011.02.067. Epub 2011 Mar 5. Review.

PMID:
21382484
14.

[Vaccination against chickenpox, shingles and rotavirus-infection].

Hartwig NG, Rümke HC, Visser HK.

Ned Tijdschr Geneeskd. 2009;153:A913. Review. Dutch.

PMID:
19900343
15.

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

Rümke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, Fassakhov R, Abad-Santos F, von Sonnenburg F, Dramé M, Sänger R, Ballou WR.

Vaccine. 2008 May 2;26(19):2378-88. doi: 10.1016/j.vaccine.2008.02.068. Epub 2008 Mar 27.

PMID:
18407382
16.
17.

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant.

Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, Dubin G; HPV Vaccine Adolescent Study Investigators Network.

J Adolesc Health. 2007 Jun;40(6):564-71.

PMID:
17531764
18.

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

Bos JM, Rümke HC, Welte R, Spanjaard L, van Alphen L, Postma MJ.

Pharmacoeconomics. 2006;24(2):141-53.

PMID:
16460135
19.

[Epidemiology of 25 years of crib death (sudden infant death syndrome) in the Netherlands; incidence of crib death and prevalence of risk factors in 1980-2004].

Rümke HC.

Ned Tijdschr Geneeskd. 2005 Jul 30;149(31):1765; author reply 1765-6. Dutch. No abstract available.

PMID:
16114297
20.

Epidemiology of nasopharyngeal carriage of Neisseria meningitidis in healthy Dutch children.

Bogaert D, Hermans PW, Boelens H, Sluijter M, Luijendijk A, Rumke HC, Koppen S, van Belkum A, de Groot R, Verbrugh HA.

Clin Infect Dis. 2005 Mar 15;40(6):899-902. Epub 2005 Feb 18.

PMID:
15736029
21.

Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.

Welte R, van den Dobbelsteen G, Bos JM, de Melker H, van Alphen L, Spanjaard L, Rümke HC, Postma MJ.

Vaccine. 2004 Dec 9;23(4):470-9.

PMID:
15530695
22.

Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations.

Postma MJ, Bos JM, Welte R, de Groot R, Luytjes W, Rümke HC, Beutels P.

Eur J Health Econ. 2004 Feb;5(1):54-7. No abstract available.

PMID:
15452765
23.

No epidemiological evidence for infant vaccinations to cause allergic disease.

Koppen S, de Groot R, Neijens HJ, Nagelkerke N, van Eden W, Rümke HC.

Vaccine. 2004 Sep 3;22(25-26):3375-85.

PMID:
15308362
24.

Reactogenicity of acellular pertussis vaccine in 4-year-olds in The Netherlands.

Keijzer-Veen MG, Holty-van der Wekken L, Juttmann RE, de Groot R, Rümke HC.

Vaccine. 2004 Sep 3;22(25-26):3256-7.

PMID:
15308347
25.

Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children.

Bogaert D, van Belkum A, Sluijter M, Luijendijk A, de Groot R, Rümke HC, Verbrugh HA, Hermans PW.

Lancet. 2004 Jun 5;363(9424):1871-2.

PMID:
15183627
26.

Pneumococcal vaccines: an update on current strategies.

Bogaert D, Hermans PW, Adrian PV, Rümke HC, de Groot R.

Vaccine. 2004 Jun 2;22(17-18):2209-20. Review.

PMID:
15149779
27.

Evaluation of diphtheria convalescent patients to serve as donors for the production of anti-diphtheria immunoglobulin preparations.

Bissumbhar B, Rakhmanova AG, Berbers GA, Iakolev A, Nosikova E, Melnick O, Ovtcharenko E, Rümke HC, Ruitenberg EJ.

Vaccine. 2004 May 7;22(15-16):1886-91.

PMID:
15121299
28.

[Childhood vaccinations anno 2004. II. The real and presumed side effects of vaccination].

Rümke HC, Visser HK.

Ned Tijdschr Geneeskd. 2004 Feb 21;148(8):364-71. Review. Dutch.

PMID:
15032089
29.

[Childhood vaccinations anno 2004. I. Effectiveness and acceptance of the Dutch National Vaccination Programme].

Rümke HC, Visser HK.

Ned Tijdschr Geneeskd. 2004 Feb 21;148(8):356-63. Review. Dutch.

PMID:
15032088
30.

Immunisation status of children adopted from China.

Schulpen TW, van Seventer AH, Rümke HC, van Loon AM.

Lancet. 2001 Dec 22-29;358(9299):2131-2.

PMID:
11784632
31.

Poliovirus circulation among schoolchildren during the early phase of the 1992-1993 poliomyelitis outbreak in The Netherlands.

Oostvogel PM, Rumke HC, Conyn-Van Spaendonck MA, van der Avoort HG, Leeuwenburg J, van Loon AM.

J Infect Dis. 2001 Dec 1;184(11):1451-5. Epub 2001 Nov 13.

PMID:
11709788
32.
33.

Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors.

Van Loveren H, Van Amsterdam JG, Vandebriel RJ, Kimman TG, Rümke HC, Steerenberg PS, Vos JG.

Environ Health Perspect. 2001 Aug;109(8):757-64. Review.

34.

Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory.

de Kleijn ED, de Groot R, Lafeber AB, Labadie J, van Limpt CJ, Visser J, Berbers GA, van Alphen L, Rümke HC.

J Infect Dis. 2001 Jul 1;184(1):98-102. Epub 2001 May 31.

PMID:
11398116
35.

Immunogenicity and safety of monovalent p1.7(h),4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations.

de Kleijn ED, de Groot R, Lafeber AB, Labadie J, van Limpt KC, Visser J, Berbers GA, van Alphen L, Rümke HC.

Vaccine. 2000 Dec 8;19(9-10):1141-8.

PMID:
11137250
36.

Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data.

de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rümke HC, Conyn-van Spaendonck MA.

Emerg Infect Dis. 2000 Jul-Aug;6(4):348-57.

37.

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age.

de Kleijn ED, de Groot R, Labadie J, Lafeber AB, van den Dobbelsteen G, van Alphen L, van Dijken H, Kuipers B, van Omme GW, Wala M, Juttmann R, Rümke HC.

Vaccine. 2000 Feb 14;18(15):1456-66.

PMID:
10618543
38.

A population-based study on tetanus antitoxin levels in The Netherlands.

de Melker HE, van den Hof S, Berbers GA, Nagelkerke NJ, Rümke HC, Conyn-van Spaendonck MA.

Vaccine. 1999 Aug 20;18(1-2):100-8.

PMID:
10501240
39.

Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study.

Vermeer-de Bondt PE, Labadie J, Rümke HC.

BMJ. 1998 Mar 21;316(7135):902-3. No abstract available.

40.

Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands.

Herremans MM, van Loon AM, Reimerink JH, Rümke HC, van der Avoort HG, Kimman TG, Koopmans MP.

Clin Diagn Lab Immunol. 1997 Sep;4(5):499-503.

41.

Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine.

de Melker HE, Conyn-van Spaendonck MA, Rümke HC, van Wijngaarden JK, Mooi FR, Schellekens JF.

Emerg Infect Dis. 1997 Apr-Jun;3(2):175-8.

42.

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine.

Peeters CC, Rümke HC, Sundermann LC, Rouppe van der Voort EM, Meulenbelt J, Schuller M, Kuipers AJ, van der Ley P, Poolman JT.

Vaccine. 1996 Jul;14(10):1009-15.

PMID:
8873396
43.

[Osteomyelitis as a complication following BCG vaccination].

Withagen MI, Ruitenberg A, van Soolingen D, Rümke HC, Diepstraten AF, de Groot R.

Ned Tijdschr Geneeskd. 1995 Oct 7;139(40):2047-50. Dutch.

PMID:
7477555
44.

Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992.

Rümke HC, Oostvogel PM, Van Steenis G, Van Loon AM.

Epidemiol Infect. 1995 Oct;115(2):289-98. Review.

45.

[Whooping cough in The Netherlands, 1989-1994].

de Melker HE, Conyn-van Spaendonck MA, Rümke HC, Sprenger MJ, Schellekens JF.

Ned Tijdschr Geneeskd. 1995 Jun 24;139(25):1280-6. Dutch.

PMID:
7609803
46.

Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation.

Gerritsen EJ, Van Tol MJ, Van 't Veer MB, Wels JM, Khouw IM, Touw CR, Jol-Van Der Zijde CM, Hermans J, Rümke HC, Radl J, et al.

Blood. 1994 Dec 15;84(12):4374-82.

47.

Are different combined vaccines needed in different parts of Europe? A point of view from a northern-European country.

Rümke HC.

Biologicals. 1994 Dec;22(4):425-7. Review. No abstract available.

PMID:
7779375
48.

[Does a modified vaccination schedule protect better against measles?].

van 't Spijker C, Rümke HC.

Ned Tijdschr Geneeskd. 1994 Nov 26;138(48):2400-5. Dutch.

PMID:
7990988
49.

[A measles epidemic in an adequately vaccinated middle school population].

van Eijndhoven MJ, Rümke HC, Bosman A, van Dijk WC, Hirsch R, van Binnendijk RS.

Ned Tijdschr Geneeskd. 1994 Nov 26;138(48):2396-400. Dutch.

PMID:
7990987
50.

[Measles in The Netherlands; epidemiology and the effect of vaccination].

van der Zwan CW, Plantinga AD, Rümke HC, Conyn-van Spaendonck MA.

Ned Tijdschr Geneeskd. 1994 Nov 26;138(48):2390-5. Dutch.

PMID:
7990986

Supplemental Content

Loading ...
Support Center